Acceptable levels of endotoxin in vaccine formulations during preclinical research

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 34-37

  Brito, Luis A ^a   Singh, Manmohan ^a  

^a Clinical Research and Development   (United States)

Author keywords

Endotoxin; Excipients; Formulation; Injectables; Preformulation; Vaccines

Indexed keywords

CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ENDOTOXIN; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; RABIES VACCINE; RECOMBINANT VACCINE; RUBELLA VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; TYPHUS VACCINE;

ARTICLE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; GENE VECTOR;

EID: 78650071105     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22267     Document Type: Article

References (20)

1. Malyala P, Singh M. 2008. Endotoxin limits in formulations for preclinical research. J Pharm Sci 97: 2041-2044.
2. FDA. 2009. General Biological Products Standards-Purity. Code of Federal Regulations Title 21(610.13).
3. Wilson M, Blum R, Dandona P, Mousa S. 2001. Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and inflammatory markers: A model of human diseases. Clin Exp Pharmacol Physiol 28: 376-380.
4. Burrell R. 1994. Human responses to bacterial endotoxin. Circ Shock 43: 137-153.
5. Cooper JF, Williams KL. 2009. Endotoxins pyrogens, LAL testing and depyrogenation. New York: Informa Healthcare.
6. Fanning MM, Wassel R, Piazza-Hepp T. 2000. Pyrogenic reactions to gentamicin therapy. N Engl J Med 343: 1658-1659.
7. CDC. 1998. Endotoxin-like reactions associated with intravenous gentamicin-California. Morb Mortal Wkly Rep 47: 877-880.
8. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS. 2000. Infant immunization with acellular pertussis vaccines in the United States: Assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 106: E51.
9. Geier DA, Geier MR. 2002. Clinical implications of endotoxin concentrations in vaccines. Ann Pharmacother 36: 776-780.
10. Moylett EH, Hanson IC. 2004. Mechanistic actions of the risks and adverse events associated with vaccine administration. J Allergy Clin Immunol 114: 1010-1020. quiz 1021.
11. Eur. P. 2008. Bacterial endotoxins. 60 5.0:2.6.14.
12. Geier MR, Stanbro H, Merril CR. 1978. Endotoxins in commercial vaccines. Appl Environ Microbiol 36: 445-449.
13. Geier MR, Geier DA, Zahalsky AC. 2003. Influenza vaccination and Guillain Barre syndrome small star, filled. Clin Immunol 107: 116-121.
14. Bolgiano B, Mawas F, Burkin K, Crane DT, Saydam M, Rigsby P, Corbel MJ. 2007. A retrospective study on the quality of Haemophilus influenzae type b vaccines used in the UK between 1996 and 2004. Hum Vaccin 3: 176-182.
15. Ochiai M, Kataoka M, Toyoizumi H, Yamamoto A, Kamachi K, Arakawa Y, Kurata T, Horiuchi Y. 2004. Endotoxin content in Haemophilus influenzae type b vaccine. Jpn J Infect Dis 57: 58-59.
16. Sen G, Khan AQ, Chen Q, Snapper CM. 2005. In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J Immunol 175: 3084-3091.
17. Wright JF. 2008. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15: 840-848.
18. Przybylowski M, Bartido S, Borquez-Ojeda O, Sadelain M, Riviere I. 2007. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. Vaccine 25: 5013-5024.
19. FDA. 1997. Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies. In Research CfBEa, editor. U.S. Department of Health and Human Services.
20. Blatteis Clark M, Sehic E, Li S. 2000. Pyrogen sensing and signaling: Old views and new concepts. Clin Infect Dis 31: S168-S177.